September 30, 2022 7:58am
“The efficiency or ease with which a security can be sold into cash without affecting its market price”; just don't jump at the first uptick
Indications: 1 Negative Indications, 1 New BUY Favorite, 2 Positive Indication with 1 Pump/Promote (BSTG – the usual suspect)
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
Why do I keep writing this blog/newsletter to inform investors, what they need to hear that others won’t say or write!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.15% or (+4 points), S&P futures are UP +0.27% or (+10 points) and NASDAQ futures are UP +0.23% or (+25 points) early in the pre-open – so far,
Stock futures rise to TRY ending the week, month and quarter on a positive note,
European markets advanced,
Asia-Pacific markets mostly lower
Henry’omics:
The stock market sold off … HARD Thursday, wiping out Wednesday's gains.
Tn Thursday, the Dow was down 1.54% or -458.13 points, the S&P 500 dropped -2.1% or -78.57 points while the Nasdaq fell -2.84% or -314.13 points.
The major indexes are also on track to end the week — and September — sharply in the red.
Interesting quote, ““The market stinks,” said Jamie Cox, managing partner of Harris Financial Group. “But that’s basically what the Fed wants: tighten financial conditions, and they believe that that will help bring down inflation to the levels that they find acceptable. And they’re using the transmission mechanism of the market to make that happen.” <CNBC>
Economic Data Docket: personal income and spending and consumer spending and the Fed’s favorite measure of inflation, the PCE deflator, is also due for August.
· The overall PCE index should show a slightly cooler 6.1% gain vs. a year earlier. But core PCE inflation is seen picking up to 4.8% from 4.6%.
RegMed Investors’ (RMi) closing bell: “another I told you so! Yesterday, I wrote: “sell into any strength with sector volume very low; and “don’t get use to Tuesday’s upside, I believe it’s transitory” … and it was!” … https://www.regmedinvestors.com/articles/12627
Ebb and flow:
Q3/22 – September – 1 holiday, 9 positive and 11 negative closes
• August – 1 neutral, 11 positive and 11 negative closes
• July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Negative Indication: Maintaining SELL …
Ultragenyx (RARE) closed down -$0.72 to $40.55 after Wednesday’s +$0.98 with a negative -$1.22 or -3.01% pre-open indication,
My new favorites - BUY:
Agenus (AGEN) closed down -$0.14 to $2.06 with a FLAT pre-open indication, if it lowers - BUY
Positive Indications:
Beam Therapeutics (BEAM) closed down -3.52 to $47.50 after Wednesday’s +$2.61, Tuesday’s +$1.85 with a positive +$0.50 or +1.05% pre-open indication,
CRISPR Therapeutics (CRSP) closed down -$2.45 to $64.49 after Wednesday’s +$3.31, Tuesday’s +$2.53, Monday’s -$2.06 after Friday’s -$1.74 with a positive +$0.59 or +0.91% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) Thursday closed FLAT with 1,100 shares traded after Wednesday’s +$1.00 with 1,545 shares traded, Tuesday’s flat ($0.00) with 2,675 shares traded, Monday’s +$0.39 with 970 shares traded and last Friday’s -$1.39 with 2,051 shares traded <3-month average = 2,095>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
- What is DST Capital?
- Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?
- Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: There is many a concern of sentiment and conviction to the cell and gene therapy sector.
Cell and gene therapy equities ended Thursday in the RED after a GREEN Wednesday, a Tuesday’s GREEN after a RED Monday – after a break from the 7X downslides in a row!
But I made MONEY on Thursday and ADDED value to a portfolio … as I had written: “sell into any strength with sector volume very low; and “don’t get use to Tuesday’s upside, I believe it’s transitory” … and it was!
September is about to end with 1 holiday, 10 positive and 11 negative closes and a Friday UNKNOWN; August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.
Another storm coming … quarter (Q3) about to close … and then back to earnings season!
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash?
Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”
That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
